Compare HMN & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | ORKA |
|---|---|---|
| Founded | 1945 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1991 | N/A |
| Metric | HMN | ORKA |
|---|---|---|
| Price | $43.17 | $32.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $46.75 | ★ $49.73 |
| AVG Volume (30 Days) | 260.0K | ★ 486.5K |
| Earning Date | 02-03-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ 57.26 | N/A |
| EPS | ★ 3.90 | N/A |
| Revenue | ★ $1,701,400,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $11.07 | ★ N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $38.76 | $5.49 |
| 52 Week High | $48.33 | $36.51 |
| Indicator | HMN | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 50.81 |
| Support Level | $42.03 | $31.15 |
| Resistance Level | $45.13 | $35.46 |
| Average True Range (ATR) | 1.09 | 1.98 |
| MACD | 0.23 | -0.33 |
| Stochastic Oscillator | 77.16 | 28.05 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.